King's College London

Research portal

Receptor-Interacting Protein 2 Gene Silencing Attenuates Allergic Airway Inflammation

Research output: Contribution to journalArticle

Fera Y. Goh, Katrina L. T. P. Cook, Nadine Upton, Lin Tao, Lin Chin Lah, Bernard P. Leung, W. S. Fred Wong

Original languageEnglish
Article numberN/A
Pages (from-to)2691-2699
Number of pages9
JournalJournal of Immunology
Issue number5
Published1 Sep 2013

King's Authors


Persistent activation of NF-kappa B has been associated with the development of asthma. Receptor-interacting protein 2 (Rip2) is a transcriptional product of NF-kappa B activation. It is an adaptor protein with serine/threonine kinase activity and has been shown to positively regulate NF-kappa B activity. We investigated potential protective effects of Rip2 gene silencing using small interfering RNA (siRNA) in an OVA-induced mouse asthma model. Rip2 protein level was found to be upregulated in allergic airway inflammation. A potent and selective Rip2 siRNA given intratracheally knocked down Rip2 expression in OVA-challenged lungs and reduced OVA-induced increases in total and eosinophil counts, and IL-4, IL-5, IL-13, IL-1 beta, IL-33, and eotaxin levels in bronchoalveolar lavage fluid. Rip2 silencing blocked OVA-induced inflammatory cell infiltration and mucus hypersecretion as observed in lung sections, and mRNA expression of ICAM-1, VCAM-1, E-selectin, RANTES, IL-17, IL-33, thymic stromal lymphopoietin, inducible NO synthase, and MUC5ac in lung tissues. In addition, elevation of serum OVA-specific IgE level in mouse asthma model was markedly suppressed by Rip2 siRNA, together with reduced IL-4, IL-5, and IL-13 production in lymph node cultures. Furthermore, Rip2 siRNA-treated mice produced significantly less airway hyperresponsiveness induced by methacholine. Mechanistically, Rip2 siRNA was found to enhance cytosolic level of I kappa B alpha and block p65 nuclear translocation and DNA-binding activity in lung tissues from OVA-challenged mice. Taken together, our findings clearly show that knockdown of Rip2 by gene silencing ameliorates experimental allergic airway inflammation, probably via interruption of NF-kappa B activity, confirming Rip2 a novel therapeutic target for the treatment of allergic asthma.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454